Page 1826 - Hematology_ Basic Principles and Practice ( PDFDrive )

1628 Part X Transplantation

Event-Free Survival (%) 64 a 71 74 b 78 68 b 64 71 a,c 57 54 a 50 56 42 b 41 47 38 c 49 48 b 48

Overall Survival (%) 71 a 72 79 b 82 75 b 69 82 a 70 57 a 59 72 c 45 b 50 60 50 62 61 b 62

Relapse (%) 18 a 13 15 15 18 b 24 16 a 24 29 a 34 30 44 b 39 36 36 28 37 b 40

NRM (%) 22 a 14 13 8 13 b 11 13 a 19 17 a 16 14 14 b 20 17 b 26 c 22 15 b 13
Selected Studies Comparing Transplant Outcomes Using Human Leukocyte Antigen–Haploidentical Versus Other Graft Sources

Chronic 55 56 42 15 38 b 25 64 a 6 d 31 a 47 d 44 c 30 53 d 13 e 33 d 51 d 12 e 45 d
Graft-Versus-Host Disease (%) Grades III–IV Grades II–IV Acute Acute – 40 – 32 – 36 – 13 6 28 c 2 13 34 62 d 15 c 28 – 41 – 48 – 28 d 7 16 13 c 33 d 8 27 17 49 c 12 40 8 27 8 25 ALL, Acute lymphocytic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CML, chronic myeloid leukemia; GIAC, granulocyte colony-stimulating factor stimulation of the donor; intensified immunosuppression leukocyte antig

Donor (n) Haplo (135) MSD (158) Haplo (231) MSD (219) Haplo (121) MSD (89) Haplo (65) Single Cord (65) Haplo (116) MUD (178) MSD (181) Haplo (MA; 104) MUD (MA; 1245) Haplo (185) MUD with ATG (241) MUD without ATG (491) Haplo (180) MSD (807) including cyclosporine A, mycophenolate mofetil, and methotrexate; antithymocyte globulin; and combination of peripheral blood and bone marrow allografts; Haplo, human leukocyte antigen haploide

AML, ALL, CML, MDS

Disease(s) AML Ph − ALL ALL Studies Employing HLA-Haploidentical SCT With High-Dose, Posttransplant Cyclophosphamide Many AML Lymphoma Lymphoma

Study Type Studies Employing GIAC Protocol for HLA-Haploidentical SCT Retrospective Prospective Biologically randomized Retrospective Retrospective Retrospective Retrospective Retrospective a Outcome at 2 years after transplant. b Outcome at 3 years after transplant. c .01 < p < .05 compared with haplo. e Outcome at 1 year after transplant. Ph, Philadelphia chromosome; SCT, stem cell transplant.

TABLE 106.1 Author, Year Lu, 2006 Wang, 2015 Wang, 2016 Mo, 2016 Bashey, 185 2016 Ciurea, 2015 Kanate, 2015 Ghosh, 187 2016 d p < .01 compared with haplo.